Evidence map›Paper›PMID 32804324›Full record

ArticleAnnals of surgical oncology2020

Ratios of miRNAs in Peritoneal Exosomes are Useful Biomarkers to Predict Tumor Response to Intraperitoneal Chemotherapy in Patients with Peritoneal Metastases from Gastric Cancer.

Hideyuki Ohzawa, Yuki Kimura, Akira Saito, Hironori Yamaguchi, Hideyo Miyato, Yasunaru Sakuma, Hisanaga Horie, Yoshinori Hosoya, Alan Kawarai Lefor, Naohiro Sata and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Cellular and Molecular Mechanisms of Chemoresistance for Gastric Cancer.International journal of general medicine · 2024
    Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Hideyuki OhzawaCenter for Clinical Research, Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan.
Yuki KimuraDepartment of Gastrointestinal Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Akira SaitoDepartment of Gastrointestinal Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Hironori YamaguchiDepartment of Gastrointestinal Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Hideyo MiyatoDepartment of Gastrointestinal Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Yasunaru SakumaDepartment of Gastrointestinal Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Hisanaga HorieDepartment of Gastrointestinal Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Yoshinori HosoyaDepartment of Gastrointestinal Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Alan Kawarai LeforDepartment of Gastrointestinal Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Naohiro SataDepartment of Gastrointestinal Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Joji KitayamaCenter for Clinical Research, Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan. kitayama@jichi.ac.jp.ORCID http://orcid.org/0000-0002-5708-7130
Jichi Medical University · JP

Funding

Japan Society for the Promotion of Science 17H04286
6 · The paper itself

Abstract

backgroundRepeat intraperitoneal (IP) chemotherapy has been successfully used for treatment of peritoneal metastases (PM) from gastric cancer (GC). Exosomes play important roles not only in tumor progression but also in chemoresistance via transfer of microRNAs (miRNAs). However, there is little evidence of an effect of miRNAs in peritoneal exosomes on chemosensitivity of peritoneal lesions.

methodsIn 74 patients with advanced GC who underwent staging laparoscopy, exosomes were isolated from peritoneal fluid and expression levels of miR-21-5p, miR-223-3p, and miR-29b-3p determined using TaqMan Advanced miRNA assays. In 43 patients with PM treated with combination chemotherapy, S-1 plus Oxaliplatin together with IP Paclitaxel, the relationship between their relative expression levels and outcomes was examined.

resultsThe ratios of miR-21-5p/miR-29b-3p and miR-223-3p/miR-29b-3p were significantly upregulated in patients with PM, especially in patients with high serum CA125 levels. They showed a mild association with Peritoneal Cancer Index (PCI) score and ascites. More impressively, the ratios were significantly higher in 16 patients with progression of PM within 1 year compared with 27 patients with an excellent tumor response (miR-21-5p/miR-29b-3p: median 17.49, range 1.83-50.90 vs. median 4.64, range 0.40-38.96, p = 0.0015, miR-223-3p/miR-29b-3p: median 1.02, range 0.23-25.85 vs. median 0.21, range 0.01-50.07, p = 0.0006). Overall survival of patients with high miR-21/miR-29b or miR-223/miR-29b ratios was significantly worse than in patients with low ratios (p = 0.0117, p = 0.0021).

conclusionsThe ratios of miRNAs in peritoneal exosome correlate with survival of the patients with PM from GC and suggest the possibility that they modify the chemosensitivity against IP chemotherapy.

Indexed as

ExosomesPeritoneal NeoplasmsStomach NeoplasmsBiomarkersBiomarkers, TumorGene Expression Regulation, NeoplasticHumansMicroRNAsBiomarkersBiomarkers, TumorMicroRNAs

Identifiers

PMID32804324
OpenAlexW3049762348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.